CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Syneos Health and Science 37 Announce Strategic Partnership

Syneos Health and Science 37 Announce...

How Machine Learning is Impacting Clinical Trials

How Machine Learning is Impacting...

Clasado Biosciences Joins Lucie Nagy as Head of Regulatory and Legal

Clasado Biosciences Joins Lucie Nagy...

Reducing the Energy Consumption of Ultra-Low Temperature Freezers

Reducing the Energy Consumption of...

Major Challenges Facing Life Science and Pharmaceutical Supply Chains

Major Challenges Facing Life Science...

Critical Bioanalytical Challenges of ADCs

Critical Bioanalytical Challenges of...

The Importance of Bioanalytical Method Validation

The Importance of Bioanalytical...

Korber Widens Its Werum PAS-X MES Service Partner Network

Korber Widens Its Werum PAS-X MES...

Syneos Health and Science 37 Announce Strategic Partnership

Syneos Health and Science 37 Announce...

How Machine Learning is Impacting Clinical Trials

How Machine Learning is Impacting...

Clasado Biosciences Joins Lucie Nagy as Head of Regulatory and Legal

Clasado Biosciences Joins Lucie Nagy...

Reducing the Energy Consumption of Ultra-Low Temperature Freezers

Reducing the Energy Consumption of...

Major Challenges Facing Life Science and Pharmaceutical Supply Chains

Major Challenges Facing Life Science...

Critical Bioanalytical Challenges of ADCs

Critical Bioanalytical Challenges of...

The Importance of Bioanalytical Method Validation

The Importance of Bioanalytical...

Korber Widens Its Werum PAS-X MES Service Partner Network

Korber Widens Its Werum PAS-X MES...

Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Joins eGenesis as an independent director

Life Sciences Review | Wednesday, August 25, 2021
Tweet

Focusing on developing human-compatible organs and cells, eGenesis appoints Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Inc., as its independent director.


FREMONT, CA: eGenesis, a gene editing and genome engineering company focusing on developing human-compatible organs and cells, appoint Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Inc., as an independent director.


“We have recently strengthened our financial position through a $125 million financing, which enables us to aggressively advance our lead kidney and islet cell product candidates towards first-in-human studies,” says Paul Sekhri, President and Chief Executive Officer of eGenesis. “Brad brings deep transactional experience across private and public financings, strategic collaborations, and acquisitions. He will provide a critical perspective to address future funding needs as we remain focused on our mission of solving the global organ shortage.”


Mr. Smith has a long history of successfully executing financial strategies for life science companies, raising nearly $1 billion in equity and debt financing. He led multiple private and public fundraising rounds at Homology Medicines, including an $83.5 million crossover round, a $166 million initial public offering (IPO), a $144 million follow-on financing, and a $60 million equity investment from Pfizer. 


Check Out This : Cannabis Business Insights


Additionally, he was instrumental in the establishment of a collaboration with the Novartis Institute of Biomedical Research. Mr. Smith previously raised nearly $200 million for Ocular Therapeutix through an initial public offering, a secondary offering, and debt financing, as well as negotiating a strategic alliance with Regeneron Pharmaceuticals. Before joining Ocular, he held financial leadership positions at several other healthcare companies, including OmniGuide Surgical, SYNARC, and PatientKeeper, Inc. He began his professional career at Coopers & Lybrand (PWC). Mr. Smith earned a B.S. in Biology from Tufts University and an MBA from New Hampshire's Whittemore School.


“I have always been attracted to ensuring truly innovative life science companies have the financial resources and partners needed to solve huge unmet medical needs,” says Mr. Smith. “eGenesis has the potential to radically improve how we treat organ failure and I look forward to working with the management team and my colleagues on the Board to transform transplantation for patients.” 


Weekly Brief

loading
Top 10 Bioanalytical Services Companies in Apac - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/bradford-smith-chief-financial-officer-cfo-of-homology-medicines-joins-egenesis-as-an-independent-director-nwid-402.html